Day: February 5, 2021

BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced the pricing of its public offering of 5,000,000 shares of its common stock at a public offering price of $30.00 per share. All of the shares are being offered by Rhythm. In addition, Rhythm has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less the underwriting discount and commission. The offering is expected to close on February 9, 2021, subject to the satisfaction of customary closing conditions.Morgan Stanley, BofA Securities, Cowen and Stifel are acting as the joint book-running managers for the offering. Canaccord...

CALGARY, Alberta, Feb. 04, 2021 (GLOBE NEWSWIRE) — Cardinal Energy Ltd. (“Cardinal” or the “Company“) (TSX: CJ; CJ.DB.A) is pleased to announce that it is issuing a notice of redemption to holders of its currently outstanding $28,207,000 8.00% Convertible Unsecured Subordinated Debentures due December 31, 2022 (the “Debentures“). The Debentures are not subject to a pre-payment penalty.As set out in the notice of redemption, Cardinal will redeem, as of March 11, 2021 (“Redemption Date“), all of the aggregate principal amount of the Debentures for cash. On the Redemption Date, Cardinal will pay the aggregate principal amount of the Debentures (being $1,000 for each Debenture) plus all accrued and unpaid interest thereon to but excluding the Redemption Date (less any tax required to be...

ZUG, Switzerland, Feb. 04, 2021 (GLOBE NEWSWIRE) — Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the pricing of its upsized initial public offering of 8,270,500 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $165.4 million. In addition, Pharvaris has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,240,575 ordinary shares at the public offering price less underwriting discounts and commissions. The ordinary shares are expected...

New York, NY , Feb. 04, 2021 (GLOBE NEWSWIRE) — Thunder Bridge Capital Partners III Inc. (the “Company”) announced today that it priced its upsized initial public offering of 36,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Capital Market (“Nasdaq”) and will begin trading tomorrow, Friday, February 5, 2021, under the ticker symbol “TBCPU”. Each unit consists of one of the Company’s shares of Class A common stock and one-fifth of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable.  Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “TBCP” and “TBCPW,” respectively.The...

MARKHAM, Ontario, Feb. 04, 2021 (GLOBE NEWSWIRE) — Sangoma Technologies Corporation (TSX VENTURE:STC), a trusted leader in delivering cloud-based Communications as a Service (“CaaS”) solutions for companies of all sizes, today announced highlights of its unaudited condensed interim consolidated financial statements for the second quarter of its fiscal year 2021 ended December 31, 2020.For the second quarter of fiscal 2021, sales were $35.32 million, 9% higher than in the same quarter last year, and EBITDA was an all-time record $6.84 million, up 32% over the same quarter last year.1 Operating Income and EBITDA are metrics used by the Company to monitor its performance and the definitions may be found in the accompanying MD&A posted today at www.sedar.com.“This was another strong quarter for Sangoma, with total sales up 9% from...

SPOKANE, Wash., Feb. 04, 2021 (GLOBE NEWSWIRE) — Avista Corp.’s (NYSE: AVA) board of directors has declared a quarterly dividend of $0.4225 per share on the company’s common stock, an increase of $0.0175 per share (4.3 percent), yielding and annualized dividend of $1.69. The common stock dividend is payable March 15, 2021, to shareholders of record at the close of business on Feb. 19, 2021.“The dividend increase approved by the board of directors marks the nineteenth consecutive year the board has raised the dividend for our shareholders. I believe it demonstrates the board’s commitment to maximizing shareholder value,” said Avista President and Chief Executive Officer Dennis Vermillion.The declaration of dividends is at the sole discretion of the board of directors. The board considers the level of dividends on a regular basis,...